Cystic Fibrosis Market in Europe 2015-2019
About Cystic Fibrosis
Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited disease. The primary symptoms of cystic fibrosis include high salt content in the sweat, breathing difficulties, secretion of abnormally viscous mucus, respiratory complications, difficulties related to digestion, and growth anomalies. Cystic fibrosis is one of the most common genetic disorders observed in Caucasian children. Rare diseases are those that affect less than 5 patients per 10,000, as defined in the EU by Rare Disease UK. Cystic fibrosis is therefore classified under rare diseases. The incidence of cystic fibrosis varies between populations. It is significantly less common in Asian and African populations compared to Caucasians (people from Europe, North America, and Australasia), with a marked difference between each country in those regions. Precise data regarding the prevalence of cystic fibrosis in Europe is not available, but it is estimated to be 1 in 8,000-10,000 individuals. Cystic fibrosis is a chronic disease and is usually progressive in nature. The onset of cystic fibrosis typically occurs in early childhood or, rarely, at birth. The principal manifestations of cystic fibrosis in patients are chronic bronchitis, pancreatic insufficiency, adolescent diabetes, pancreatitis, male sterility, and very rarely intestinal obstruction or liver cirrhosis. The mortality and morbidity of patients are dependent on the degree of bronchopulmonary involvement.
TechNavio's analysts forecast the Cystic Fibrosis market in Europe to grow at a CAGR of 35.10 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Cystic Fibrosis market in Europe for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of cystic fibrosis including:
TechNavio Announces the Publication of its Research Report – Cystic Fibrosis Market in Europe 2015-2019
TechNavio recognizes the following companies as the key players in the Cystic Fibrosis Market in Europe: Actavis plc, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Novartis AG and Vertex Pharmaceuticals Inc.
Other Prominent Vendors in the market are: Abbott, Anthera Pharmaceuticals, Arcturus Therapeutics, Boehringer Ingelheim, Chiesi Farmaceutici, Corbus Pharmaceuticals, Genzyme, Insmed, Johnson & Johnson, Merck Sharp & Dohme, Neovii Biotech, Novo Nordisk, PharmaSwiss, Pharmaxis, Proteostasis Therapeutics, PTC Therapeutics, United Medical and Venus Remedies.
Commenting on the report, an analyst from TechNavio’s team said: “Growing awareness among the medical fraternity, patients, and families of patients is one key trend being witnessed in this market. This increases the number of patients seeking treatment and results in growth in the overall consumption of medicines.”
According to the report, High unmet medical needs are one of the major factors propelling the growth of the market. Current treatment options cannot cure the disease completely and, hence, the resultant mortality rate is high. Therefore, drugs that can cause disease remission in patients are expected to drive the growth of the market.
Further, the report states that high cost of drugs is one of the major challenges restricting the growth of the market. Drugs used for the treatment of cystic fibrosis are expensive and, hence, get a poor response from patients. Patients also tend to withdraw from expensive treatment regimens.
Actavis, F. Hoffmann-La Roche, Gilead Sciences, Novartis, Vertex Pharmaceuticals , Abbott, Anthera Pharmaceuticals, Arcturus Therapeutics , Boehringer Ingelheim , Chiesi Farmaceutici, Corbus Pharmaceuticals, Genzyme, Insmed, Johnson & Johnson ,Merck Sharp & Dohme, Neovii Biotech, Novo Nordisk, PharmaSwiss , Pharmaxis , Proteostasis Therapeutics, PTC Therapeutics, United Medical, Venus Remedies
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook